The VIVA Trial

20031,018 citationsJournal Article

Authors

Timothy D. Henry · Los Angeles Medical Center

Brian H. Annex · Los Angeles Medical Center

George R. McKendall · Los Angeles Medical Center

Michael Azrin · Los Angeles Medical Center

John J. López · Los Angeles Medical Center

Frank J. Giordano · Los Angeles Medical Center

PK Shah

Abstract

rhVEGF seems to be safe and well tolerated. rhVEGF offered no improvement beyond placebo in all measurements by day 60. By day 120, high-dose rhVEGF resulted in significant improvement in angina and favorable trends in ETT time and angina frequency.

Topics & Keywords

Angiogenesis and VEGF in Cancer Coronary Interventions and Diagnostics Cardiac Imaging and Diagnostics

UN Sustainable Development Goals

Responsible consumption and production

Publication Details

Published in: Circulation

Volume 107, Issue 10, pp. 1359-1365

DOI: 10.1161/01.cir.0000061911.47710.8a

Field-Weighted Citation Impact: 24.14